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Key Points
• Terminally differenti-
ated CD56neg NK cells
expand in children after
chronic malaria expo-
sure and in those
diagnosed with eBL.
•NK cells in eBL patients
express high levels of
MIP-1b in lieu of TNF-a,
and normal NK cell
profiles appear to be
restored in eBL
survivors.
Natural killer (NK) cells are critical for restricting viral infections and mediating tumor
immunosurveillance. Epstein-Barr virus (EBV) and Plasmodium falciparum malaria are
known risk factors for endemic Burkitt lymphoma (eBL), the most common childhood
cancer in equatorial Africa. To date, the composition and function of NK cells have not been
evaluated in eBL etiology or pathogenesis. Therefore, using multiparameter ﬂow cytometry
and in vitro killing assays, we compared NK cells from healthy children and children
diagnosed with eBL in Kenya. We deﬁned 5 subsets based on CD56 and CD16 expression,
including CD56negCD16pos. We found that licensed and terminally differentiated perforin-
expressing CD56negCD16pos NK cells accumulated in eBL children, particularly in those with
high EBV loads (45.2%) compared with healthy children without (6.07%) or with (13.5%)
malaria exposure (P 5 .0007 and .002, respectively). This progressive shift in NK cell
proportions was concomitant with fewer CD56dimCD16pos cells. Despite high MIP-1b
expression, CD56negCD16pos NK cells had diminished cytotoxicity, with lower expression of
activation markers NKp46, NKp30, and CD160 and the absence of TNF-a. Of note, the
accumulation of poorly cytotoxic CD56negCD16pos NK cells resolved in long-term eBL
survivors. Our study demonstrates impaired NK cell–mediated immunosurveillance in eBL
patients but with the potential to restore a protective NK cell repertoire after cancer
treatment. Characterizing NK cell dysfunction during coinfections withmalaria and EBV has
important implications for designing immunotherapies to improve outcomes for children
diagnosed with eBL.
Introduction
Endemic Burkitt lymphoma (eBL) is a pediatric Epstein-Barr virus (EBV)–associated B-cell malignancy that
occurs in malarious regions of equatorial Africa.1 Children at risk for eBL experience their primary EBV
infection before 2 years of age, accompanied by repeated Plasmodium falciparum (Pf) coinfections and
episodes of viral reactivation resulting in higher EBV loads.2-4 Malaria is postulated to diminish EBV-specific
T-cell immune surveillance in eBL etiology.5-12 However, the complementary role of natural killer (NK) cells
in viral and tumor immunosurveillance has not been studied within the context of eBL pathogenesis.
NK cell immunosurveillance involves orchestrating activation and inhibitory signals to identify virally
infected or tumorigenic cells.13-16 Killer cell immunoglobulin-like receptors (KIRs; reviewed in
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Lanier17 and Saunders et al18) interact with human leukocyte
antigen (HLA) class I molecules for target cell recognition,15,19,20
distinguishing “self” from “nonself.” NK cells also receive co-
ordinated signals from other cell surface receptors that determine
their cytolytic function or lack thereof: the NKG2 family induces
inhibitory signals (via NKG2A) or activation signals (via NKG2C
and NKG2D),21 and natural cytotoxicity receptors (NCRs) are
crucial for triggering cytotoxic activity and targeted cell death
(reviewed in Kruse et al22).
In addition to the well-characterized CD56brightCD16neg,
CD56dimCD16pos NK cells, an increase in the CD56dimCD16neg
NK cell subset with a concomitant decrease in CD56dimCD16pos
proportions has been observed after coculture with the K562 tumor
cell line or cytokine cocktails in healthy American donors.23,24 The
presence of surface metalloproteases appears to regulate CD16
expression after degranulation.23,24 Another NK cell subset,
CD56negCD16pos, has been described in HIV-viremic and hepatitis C
virus–infected adults, particularly those who failed hepatitis C virus
treatment.25-28 Compared with CD56pos NK cells, this subset has
been characterized as “dysfunctional” because of its lower expression
of activating receptors and cytokine production.
EBV, like most herpesviruses, has evolved to evade immune clearance
and, therefore, is able to persist as a life-long asymptomatic infection in
immunocompetent individuals.29 A recent study described a role for
viral microRNAs in mediating immune evasion from CD8 T cells30;
however, little is known about NK cell immune escape mechanisms
indulgent of EBV-infected B cells. Clues from studying EBV infection
during adolescence that results in acute infectious mononucleosis
suggest that a distinct CD56dimCD16posNKG2AposKIRneg NK cell
subset expands and accompanies disease resolution.31 Studies of
human cytomegalovirus (CMV) revealed an accumulation of a
CD56dimCD16posCD57posNKG2Chigh NK cell subset during CMV/
EBV coinfection that was not found in children who were infected
only with EBV.32,33 “Memory-like” NKG2Cpos NK cells found in
patients receiving bone marrow or peripheral blood stem cell
transplants from CMVpos donors displayed more durable IFN-g
production compared with NK cells from CMVneg donors.34 NK cell
subset phenotypes and cytotoxic capacity during asymptomatic
pediatric EBV infections are not known.
Studies of malaria infections in African children have reported high
IL-12 and IL-18 plasma levels compared with children without
malaria.35,36 These cytokines are essential to induce IFN-g
secretion by NK cells in response to Pf-infected red blood cells
(Pf-iRBCs) in vitro.37 This model identified IFN-g secretion pre-
dominantly from CD56pos cells during peripheral blood mono-
nuclear cell (PBMC)/Pf-iRBC coculture experiments.37 Cytotoxic
CD56dimCD16pos NK/NK T cells and CD8pos T cells are protective
against malaria38; however, EBV or CMV coinfections were not
evaluated in their study populations.
To improve our understanding of NK cell composition and function
during malaria and EBV coinfections in children, as well as how NK cell
alterations may contribute to eBL pathology, we compared healthy
children with divergent malaria exposure histories and children
diagnosed with eBL in Kenya. We characterized NK cell subset
frequencies and function by flow cytometry and in vitro killing assays,
with further stratification of children by peripheral blood EBV load. In
addition, we conducted evaluations of NK cell subset phenotypes and
functions in eBL survivors.
Methods
Study participants
Children with suspected eBL were enrolled at Jaramogi Oginga
Odinga Teaching and Referral Hospital between 2003 and 2011.39
Two independent pathologists in Kenya confirmed the diagnosis by
cytopathology and May-Gru¨nwald Giemsa staining. In this region,
eBL is the most common pediatric cancer; 95% of children clinically
suspected of having the disease are pathologically confirmed with
eBL. Samples from our biorepository were further characterized by
transcriptome and mutational profiling to confirm eBL diagnosis40
and were found to be 90% concordant with the initial diagnosis. For
cancer patients, baseline samples were collected before induction
of chemotherapy and, for those in remission, 3 and 9 months later.
Age-matched healthy Kenyan controls were selected and strati-
fied based on divergent malaria exposure histories and correlated
EBV loads.2,39 Nandi children experience low exposure to malaria
infections and have been shown previously to harbor low EBV
loads.2,4 They also reside in an area with a low incidence of eBL.41
In contrast, Kisumu children reside in a high malaria–transmission
region (ie, holoendemic malaria), experience higher EBV loads, and
reside in an area with a higher incidence of eBL.41 After obtaining
written informed consent from parents, PBMCs from children with
eBL were compared with those from Kisumu children (with malaria)
and Nandi children (without malaria). All children in this study were
EBV seropositive, HIV-negative, and born of HIV-negative mothers.
Ethical approval was obtained from the Kenya Medical Research
Institute and the University of Massachusetts Medical School.
Flow cytometry phenotyping, functional assays,
EBV viral load, IgG levels in plasma, and
statistical analysis
See supplemental Methods for details.
Results
Study population characteristics
The 3 groups of children did not differ significantly with regard to
median age (Nandi: 6 years, range 2.5-6; Kisumu: 6.5 years, range 2.5-
6.5; and eBL: 6.1 years, range 2.5-7.9), sex, or absolute lymphocyte
counts (.2000 cells/mm3). Serology profiles confirmed expected
malaria exposure histories, with eBL patients and Kisumu children
having higher antibody titers to malaria antigens compared with Nandi
children (supplemental Figure 1). All of the children included in this
analysis were EBV seropositive. None of the children had malaria
blood-stage infections at the time of blood collection (data not shown).
The survival rate for eBL children included in this study was 57%,
similar to our larger study cohort.39 Our eBL group was divided into 2
subgroups based on EBV status: no/low EBV loads detected in
peripheral blood by quantitative polymerase chain reaction and high
EBV copy numbers (.3 log EBV copies per microgram of DNA). This
threshold was determined previously in comparisons of healthy Kisumu
and eBL children.42
CD56negCD16pos NK cells accumulate in eBL patients
Overall, no statistical differences were observed among the 3
groups of children with regard to the frequency of total NK cells
(Figure 1A), although we noted that our study populations had
generally lower frequencies (median 3.06% for healthy and 2.84%
1102 FORCONI et al 22 MAY 2018 x VOLUME 2, NUMBER 10
for eBL) compared with healthy children fromCameroon (median 8%
for 2- to 6-year-old children).43 We examined 5 subsets defined
by CD56 and CD16 expression (gating strategy is shown
in supplemental Figure 2): CD56brightCD16neg, CD56brightCD16pos,
CD56dimCD16pos, CD56dimCD16neg, and CD56negCD16pos
(Figure 1B). We observed significantly more CD56negCD16pos NK
cells in eBL patients with high EBV loads (median 45.2%) compared
with Kisumu (median 13.5%) and Nandi (median 6.07%) children
(P5 .002 and .0007, respectively; Figure 1C). This observation was
concomitant with a lower median number of CD56dimCD16pos NK
cells in eBL patients with high EBV loads (22.2%) and no/low EBV
(39.7%) compared with Nandi children (67.25%) (P 5 .002 and
.003, respectively). Interestingly, we observed the same NK cell
subset skewing between the 2 groups of healthy children: Kisumu
children had significantly lower CD56dimCD16pos (median 45.85%;
P 5 .02) and higher CD56negCD16pos (median 13.5%; P 5 .006)
NK cells compared with Nandi children (median 67.25% and 6.07%,
respectively). This alteration in relative NK cell subset proportions is
illustrated in Figure 1D using representative flow cytometry plots from
children within each group.
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Figure 1. Characterization of NK cell subsets in Kenyan children. Children were categorized by malaria and EBV exposure, as well as eBL diagnosis: Nandi
(EBVlow/malarialow; n 5 10), Kisumu (EBVhigh/malariahigh; n 5 10), and eBL patients (n 5 14) with no/low EBV and high EBV loads. (A) The percentage of NK cells within the
circulating lymphocytes was defined as the number of NK cells (CD56pos and/or CD16pos)/total number of live lymphocytes. (B) Five NK cell subsets were defined by CD56
and CD16 expression levels: CD56brightCD16neg, CD56brightCD16pos, CD56dimCD16neg, CD56dimCD16pos, and CD56negCD16pos. (C) Percentages of NK cell subsets for
each group of children within our study. (D) Representative proportions of NK cell subsets in different groups of children. Data in panels A and C are mean 6 standard
deviation (SD). *P , .05, **P , .01, ***P , .001.
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The significantly higher proportion of CD56negCD16pos NK cells
in eBL and Kisumu children compared with healthy Nandi
children suggests that their enrichment might be due to higher
infectious disease burdens. We found that the percentage of
CD56negCD16pos cells in eBL children correlated with higher
antimalarial (AMA1, MSP1, and Pf SEA-1A antigens) antibody
titers (P 5 .006, .007, and .01, respectively; supplemental
Figure 3) but not with antibodies from other infectious dis-
eases, such as schistosomiasis, measles, and CMV. It was not
surprising to find no correlation with EBV antibody titers using a
single time point, because our past studies have demon-
strated longitudinal variability in EBV antibody titers.3,44 How-
ever, malaria antibody profiles have been used as an indicator of
cumulative and recent past exposure in the absence of an active
infection.45
KIR licensing in malaria-exposed and eBL children
favors inhibitory signals
As expected, we observed lower expression of activating and
inhibitory KIRs (KIR2DL1/S1, KIR2DL1/S5, KIR2DL2, KIR2DL3,
and KIR3DL1) on CD56brightCD16neg NK cells compared with
other NK cell subsets across all of our study populations (Figure 2),
confirming their immature nonlicensed status. Coinciding with NK
cell maturation, KIR expression was elevated on CD56brightCD16pos
and CD56dimCD16pos subsets in all groups of children. However,
KIR2DL1/S1 levels did not decrease in CD56negCD16pos NK cells
0
1 2 3 4 1 2 3 4 1 2 3 4
10
20
30
40
50
60
%
 o
f K
IR
2D
L1
S1
 p
os
itiv
es
 c
ell
s Nandi Kisumu BL
***
**
**
***
**
*
1 2 3 4 1 2 3 4 1 2 3 4
0
20
40
60
80
%
 o
f K
IR
2D
L2
 p
os
itiv
es
 c
ell
s Nandi Kisumu BL
* **
**
**
0.08
0.05
1 2 3 4 1 2 3 4 1 2 3 4
0
10
20
30
40
%
 o
f K
IR
3D
L1
 p
os
itiv
es
 c
ell
s
Nandi Kisumu BL
****
****
***
****
**
*** **
* *
1 2 3 4 1 2 3 4 1 2 3 4
0
20
40
60
80
%
 o
f p
er
fo
rin
 p
os
itiv
es
 c
ell
s
Nandi
* ***
**
***
*
*
0.05
n.s
0.05
Kisumu BL
0
10
20
30
50
40
%
 o
f K
IR
3D
L1
 p
os
itiv
es
 c
ell
s
Nandi Kisumu BL
*
*
CD56negCD16pos subset
1 2 3 4 1 2 3 4 1 2 3 4
0
Nandi Kisumu BL
20
10
30
40
50
%
 o
f K
IR
2D
L3
 p
os
itiv
es
 c
ell
s
1 2 3 4 1 2 3 4 1 2 3 4
Nandi Kisumu BL
** **
**
**
0.08
*
0
10
20
30
40
50
60
%
 o
f K
IR
2D
L1
S5
 p
os
itiv
es
 c
ell
s
Number Color CD56 CD16
1 Green Bright Negative
2 Blue Bright Positive
3 Pink Dim Positive
4 Red Neg Positive
A B
C D
E F
G H
Figure 2. Comparison of KIR and perforin expression by different NK cell subsets for Nandi, Kisumu, and eBL children. Comparison of KIR2DL1S1 (A),
KIR2DL1S5 (B), KIR2DL2 (C), KIR2DL3 (D), and KIR3DL1 (E) among the different NK cell subsets: CD56brightCD16neg (1), CD56brightCD16pos (2), CD56dimCD16pos (3), and
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1104 FORCONI et al 22 MAY 2018 x VOLUME 2, NUMBER 10
in malaria-exposed and eBL children in contrast to Nandi children,
who had significantly lower KIR2DL1/S1 expression levels for this
subset (Figure 2A). With regard to KIR2DL1/S5 expression
(Figure 2B), Nandi children expressed this inhibition/activation
marker on CD56brightCD16pos and CD56dimCD16pos NK cell
subsets, whereas Kisumu and eBL children had lower expression
of this KIR for all NK cells. The expression pattern of inhibitory
receptors KIR2DL2 and KIR2DL3 (Figure 2C-D, respectively) was
significantly lower on all NK cells from eBL patients compared with
the highest levels in Kisumu children and intermediate levels in
Nandi children. In contrast, expression of the KIR3DL1 inhibitory
receptor (Figure 2E) increased across NK cell subsets for eBL
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Figure 3. Expression of NKp30, NKp46, and CD161 consistent with an adaptive NK cell phenotype. NK cell subsets, including CD56brightCD16neg (1),
CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4), were evaluated for each group of children: Nandi (EBVlow/malarialow), Kisumu (EBVhigh/malariahigh),
and eBL patients with low EBV and high EBV load. Comparison of NKp30 (A) and NKp46 (B) expression on the different NK cell subsets across all study groups. NKp30 (C)
and NKp46 (D) expression on CD56negCD16pos NK cell subsets across study groups. Nandi, n 5 10; Kisumu, n 5 8; and BL, n 5 11 for NCRs. (E) Comparison of CD161 on
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patients, with the highest levels on CD56dimCD16pos and
CD56negCD16pos NK cell subsets. Kisumu children had higher
KIR3DL1 expression on mature CD16pos NK cell subsets compared
with Nandi children. Comparing KIR3DL1 on the CD56negCD16pos
NK cell subset across groups of children (Figure 2F), we observed
significantly higher expression for Kisumu and eBL children
compared with Nandi children (P 5 .04 and .01, respectively).
Finally, basal levels of perforin expression (Figure 2G) were higher for
CD56dimCD16pos and CD56negCD16pos NK cell subsets com-
pared with CD56bright NK cell populations for all children in our study,
with no statistically significant difference between CD56dimCD16pos
and CD56negCD16pos NK cell subsets. This suggests that
CD56negCD16pos NK cells, which are highly enriched in eBL
children, are licensed for cytotoxic functions, yet their KIR profiles
differ dramatically from those of healthy Nandi children.
CD56negCD16pos NK cell subset found in eBL patients
displays features of adaptive NK cells
To determine the phenotype (canonical vs adaptive) of the
CD56negCD16pos NK cell subset, we checked the presence of
activation and cytotoxic receptors. To evaluate the NCR pathways,
we compared NKp30 and NKp46 expression across study populations
and among the different NK cell subsets. We noted significantly
lower expression of NKp30 and NKp46 for CD56negCD16pos NK
cells compared with CD56brightCD16neg and CD56brightCD16pos NK
cell subsets from all investigated groups of children (Figure 3A-B).
Interestingly, expression of NKp30 and NKp46 was lowest on
CD56negCD16pos NK cells in eBL children with the highest EBV loads
compared with eBL children with low EBV titers and both healthy
groups of children (Figure 3C-D). In addition, among the healthy
children, Kisumu children had significantly lower expression of NKp46
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groups (Nandi, n 5 8; Kisumu, n 5 6; and BL, n 5 11). 2B4 expression by NK cells subset representation (C) and by linear representation (D) across study groups (Nandi,
n 5 6; Kisumu, n 5 4; and BL, n 5 10). Data are mean 6 SD. *P , .05, **P , .01, ***P , .001.
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Figure 5. Absence of the CD57/NKG2C NK cell phenotype otherwise found in HCMV-EBV coinfection. NK cell subsets, including CD56brightCD16neg (1),
CD56brightCD16pos (2), CD56dimCD16pos (3), and CD56negCD16pos (4), were evaluated for each group of children: Nandi (EBVlow/malarialow), Kisumu (EBVhigh/malariahigh),
and eBL patients with no/low EBV and high EBV loads. (A) Comparison of CD57 among the different NK cell subsets across study groups. (B) CD57 expression on the
CD56negCD16pos NK cell subset across study groups. (C) Comparison of NKG2C expression among different NK cell subsets across groups of children. (D) NKG2C
expression on the CD56negCD16pos NK cell subset across study groups. (E) Median fluorescence intensity (MFI) of antibody titers against CMV. (F) Coexpression of CD57
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on CD56negCD16pos NK cells compared with Nandi children (P5 .04),
suggesting an impairment in anti-infection rather than antitumor immune
surveillance.
We also examined expression of CD161, which was lowest on the
CD56negCD16pos NK cell subset from eBL children compared with
the respective NK cells in Nandi and Kisumu children (Figure 3E-F).
CD160 displayed a similarly downregulated expression pattern
for eBL patients compared with healthy children (supplemental
Figure 4). Interestingly, coexpression analysis revealed dimin-
ished double-positive CD160posCD161pos NK cells, as well as
CD160negCD161pos NK cells, in eBL patients compared with
healthy controls (supplemental Figure 5). Finally, and contrary to a
previous study of HIV-infected adults that described lower CD94/
NKG2A marker expression for the CD56negCD16pos NK cell
subset,28 we observed no differences for this set of NK cell
markers across our study populations (supplemental Figure 6).
Together, our results suggest that CD56negCD16pos NK cells display a
terminally differentiated phenotype, with eBL patients unable to control
EBV showing further impairments in NK cell activation markers. This
would limit potent NK cell activation and is consistent with poor cytotoxic
function of NK cells from eBL children with extremely high EBV loads. It
is worthwhile to note that this suppressed activation profile was not
observed on the CD56negCD16pos NK cell subset of eBL patients with
low EBV loads and Nandi children. Based on these observations, we
speculate that this NK cell phenotypemay not be induced in response to
tumor cells but rather by the high viral loads experienced by children
residing in malaria holoendemic areas prior to tumorigenesis.
NKG2D and 2B4 coactivating receptors expressed by
the CD56negCD16pos NK cell subset
We found that eBL children with low EBV loads had significantly
higher NKG2D expression on most of their NK cell subsets
(Figure 4A). We also noted that NKG2D expression patterns across
NK cell subsets were similar among all groups of children and
appear to correlate with CD56 expression (Figure 4B). Further-
more, we found no differences among groups of children for 2B4
expression on NK cell subsets, with the exception of lower
expression on CD56dimCD16neg cells relative to CD56negCD16pos
cells for high EBV eBL children (Figure 4C). Overall, 2B4 was
expressed on .50% of cells within each NK cell subset and
increased after CD16 upregulation (Figure 4D). However, it is
interesting to note the inverse correlation between NKG2D and
2B4 expression for some NK cell subsets but not others (compare
Figure 4B and 4D). These differences in NKG2D and 2B4
expression suggest that target cells with NKG2D ligands are
recognized more efficiently by CD56bright NK cells, whereas those
with 2B4 ligands preferentially stimulate CD56dim NK cells.
Absence of CD57posNKG2Cpos NK cell expansion in
eBL children
CD57 was highly expressed on CD56dimCD16pos NK cells, with the
overall expression pattern across NK cell subsets not differing
among our study groups (Figure 5A). CD57 expression was
the lowest on CD56negCD16pos NK cells for eBL children with
high EBV loads; however, this trend did not achieve statistical
significance (Figure 5B). Despite higher expression of NKG2C
described on NK cells cocultured with Pf-iRBCs,46 we found no
differences in NKG2C expression in circulating NK cells associated
with malaria exposure or EBV load (comparing Kisumu and Nandi
children). In contrast, eBL children with high EBV loads had the
lowest expression of NKG2C on all of their NK cell subsets
compared with the other groups of children (Figure 5C). NKG2C
expression on the CD56negCD16pos subset was significantly
lower in eBL children with high EBV loads compared with those
with low EBV loads (Figure 5D; P 5 .03). To eliminate a potential
effect modifier, we observed no significant difference in sero-
positivity or antibody titer to human CMV (HCMV) among our
groups of children (Figure 5E). In addition, the percentage of
double-positive CD57posNKG2Cpos NK cells seemed to be
lower in the CD56negCD16pos NK cell subset compared with
the CD56dimCD16pos NK cell population (Figure 5F). This was
particularly noticeable for Nandi and eBL children with low EBV loads
(Figure 5G), who had more CD57posNKG2CposCD56dimCD16pos NK
cells than CD57posNKG2CposCD56negCD16pos NK cells (P 5 .01
and .01, respectively). These observations demonstrate that, even in
healthy HCMV-infected children, CD57posNKG2Cpos NK cells were
not expanded by EBV or malaria infections; however, this population
of double-positive NK cells was found to be elevated in eBL children
with low viral loads compared with those with high viral loads
(Figure 5G). These findings suggest that high EBV loads and
eBL tumor formation do not drive the formation of terminal “memory-
like” NK cells, which has been associated with control of viral
reactivation in HCMV.34,47
MIP-1b cytokine production by NK cells in eBL
patients after K562 cell stimulation
To analyze cytokine production and degranulation as a surrogate for
cytotoxicity, we combined Nandi and Kisumu children into 1 group
of “healthy children” and compared them with eBL patients
(irrespective of EBV load). Nearly all NK cell subsets from eBL
children expressed MIP-1b upon K562 cell stimulation, including
CD56negCD16pos cells (Figure 6A). MIP-1b is known to activate
the synthesis and release of other proinflammatory cytokines,
such as TNF-a.48 However, NK cells from eBL children were less
able to produce TNF-a compared with healthy children, who
had more robust responses (Figure 6B). CD56brightCD16neg,
CD56dimCD16neg, and CD56dimCD16pos NK cell subsets from
healthy children expressed significantly more TNF-a after stimula-
tion, whereas all subsets from eBL children remained low
and unchanged. No significant difference was observed between
healthy and eBL children for IFN-g production or CD107a
expression, irrespective of NK cell subset and after K562
cell stimulation (supplemental Figure 7). Focusing on the
CD56dimCD16pos and CD56negCD16pos NK cell subsets, we
noted no difference in the production of the cytokines analyzed
Figure 5. (continued) and NKG2C on CD56dimCD16pos and CD56negCD16pos NK cells. (G) CD57posNKG2Cpos expression between CD56dimCD16pos and
CD56negCD16pos subsets across study groups. For CD57, Nandi, n 5 8; Kisumu, n 5 6, and BL, n 5 11. For NKG2C, Nandi, n 5 7; Kisumu, n 5 5; and BL, n 5 11. Data
are mean 6 SD. *P , .05, **P , .01, ***P , .001.
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(Figure 6C). This observation supports our hypothesis that
the CD56negCD16pos NK cell subset originates from the
CD56dimCD16pos NK cell population. We noted that the proportion
of CD56dimCD16neg NK cells seemed to expand after K562 cell
stimulation compared with the unstimulated conditions for all
groups of children (supplemental Figure 8). This is consistent with
another study24 describing the loss of CD16 expression after
degranulation of CD56dimCD16pos NK cells. Our experiments were
not designed to determine the differentiation pathways giving rise to
the different KIR-licensed NK cell subsets; however, this observa-
tion provides rationale for further study.
Decrease in CD56negCD16pos NK cells in eBL survivors
To determine whether skewed NK cell profiles found in eBL children
would naturally re-equilibrate to resemble those found in normal
Nandi children, we tracked NK cell profiles in 2 eBL survivors (with
low EBV loads) over time: time point 1 was considered the time of
diagnosis and prior to induction of chemotherapy, with repeated
samples collected during remission at 3 and 9 months after
diagnosis (time points 2 and 3, respectively). We noted markedly
different rates of natural NK reconstitution for each patient
(Figure 7A). However, we found markedly fewer CD56negCD16pos
NK cells in both patients by 9 months postdiagnosis (Figure 7B-C),
resulting in the same low levels found in healthy children described
above. The proportions of immature CD56brightCD16neg and mature
CD56dimCD16pos NK cell subsets also reached levels comparable
to those in healthy children. Focusing on the CD56negCD16pos NK
cell subset, we selected a panel of NK cell markers found to be
important in the comparative studies described above and mea-
sured them longitudinally in eBL survivors (Figure 7D). We
observed higher expression over time for most of the cytotoxic
markers, including NKp46, NKp30, and CD161, on the surface of
the CD56negCD16pos NK cell subset from 1 eBL patient. For
patient “BL2” (Figure 7D), the expression of these markers is
influenced by the fact that a different composition of NK cell
subsets developed over time compared with “BL1.” We also
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Figure 6. MIP-1b production and degranulation of CD56neg CD16pos NK cell subset after K562 cell stimulation. PBMCs from healthy children (Nandi and Kisumu;
n 5 7) and eBL children (n 5 7) were stimulated with K562 cells in a functional in vitro killing assay. NK cell subsets were defined by CD56 and CD16 expression levels.
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checked the coexpression of cytotoxic NCR markers and found a
decrease in NKp30/NKp46, as well as in NKp30/2B4 and NKp46/
2B4. For both eBL patients (Figure 7E-F), these cells “reappeared”
9 months after chemotherapy and arrived at the same proportion as
observed in Nandi children (Figure 7F). A limitation of this secondary
analysis is the small sample size, but results from 2 randomly selected
patients are provocative. This longitudinal glimpse of the proportional
and expression marker changes in NK cell subsets, albeit preliminary,
suggests that NK cell composition can eventually recover to normal
parameters in eBL survivors. Future studies with more patients would
need to be conducted to determine whether poor long-term outcomes
are due to a lag in the ability to re-establish normal NK cell profiles.
Discussion
To begin to evaluate the role of NK cells in eBL etiology, our study
compared healthy EBV-infected Kenyan children with those
diagnosed with eBL and demonstrated that NK cell subsets were
dramatically altered by Pf coinfections and even more so during
this childhood cancer. We found significantly more terminally
differentiated CD56negCD16pos NK cells in eBL patients with the
highest EBV loads compared with healthy children. In addition,
eBL children had specific defects in NK cell functions compared
with healthy children, including lower TNF-a secretion, despite no
overall differences in IFN-g secretion and degranulation, as
measured by CD107a after K562 cell stimulation. In contrast,
NK cells from eBL children more readily secreted MIP-1b
compared with healthy children, which could be a last-ditch effort
by NK cells to recruit proinflammatory cells to help kill the cancer
cells. Our examination of eBL survivors demonstrates that a
healthy NK cell repertoire can be re-established; however, the
mechanisms responsible, be they NK cell reconstitution or
phenotypic restoration, have yet to be determined.
Our study confirmed that CD56negCD16pos NK cell subsets are
licensed; however, KIR expression profiles varied, depending on
malaria exposure and cancer diagnosis. In fact, except for higher
expression of KIR3DL1 on all NK cell subsets, lower expression of
other KIRs was found for eBL patients compared with healthy
children. Combined with lower expression of activating receptors,
this suggests that the threshold for NK cell activation is elevated in
eBL patients. Interestingly, malaria-exposed Kisumu children also
had higher KIR3DL1 expression within their CD56negCD16pos NK
cell subset compared with Nandi children, suggesting that this may
be a mechanism by which malaria subverts NK cell–mediated
immunity. In other infectious disease contexts, including AIDS,
variant KIR3DL1 alleles influence disease progression after
activation by HLA-Bw4.49 Interestingly, higher expression of the
KIR3DL1*015 allele is observed in HIV-infected adult African
Americans compared with European Americans, and this particular
allele has higher binding for HLA-Bw4.18,50 Future studies of eBL
etiology will incorporate HLA and KIR genotypes in individual
assessments of NK cell function, because higher responses to
Pf-iRBCs have been reported for KIR3DL2pos NK cells.51
In addition to shifts in NK cell subset proportions and expres-
sion of licensing markers, we evaluated NKp30 and NKp46,
which can be activated by the Pf erythrocyte membrane protein
1 (reviewed in Kruse et al22) and induce cytotoxic activity against
Pf-iRBCs.36-38,52 However, our studies showed dramatically lower
expression of these NCRs on NK cells from eBL children with
extremely high EBV loads, as well as significantly lower NKp46
expression on NK cells from Kisumu children compared with Nandi
children. This suggests that the burden of infectious diseases may
be downregulating these receptors, independent of tumorigenesis.
In support of this premise, albeit exploratory, we had the opportunity
to evaluate NK cell subset proportions in Kenyan children enrolled in
our study who were diagnosed with cancers other than eBL.
Interestingly, we found that CD56negCD16pos NK cells accumu-
lated in a pediatric patient with non-Hodgkin lymphoma who had a
high EBV load commensurate with eBL patients. In contrast,
patients with Hodgkin lymphoma and nephroblastoma who had low
or no detectable viremia had few CD56neg NK cells, comparable to
healthy children (supplemental Figure 9).
The role of CD16 is to drive antibody-dependent cellular cy-
totoxicity (ADCC),53 and cytokine production after CD16 activa-
tion is elevated in adaptive NK cells compared with canonical
NK cells.54,55 Therefore, canonical NK cells are able to induce
cytotoxicity against other immune cells56 instead of adaptive NK
cells with less immunoregulatory function. Interestingly, the accu-
mulation of CD56negCD16pos NK cells in eBL children accom-
panied decreased TNF-a production in target cell–killing assays.
However, these children have robust IgG antibodies to EBV and
malaria antigens, suggesting potential engagement of ADCC-
mediated killing.57,58 Future studies using autologous lymphoblas-
toid cell lines and eBL tumor cell lines will allow us to directly assess
which NK cell subsets are involved in ADCC and to what extent they
affect innate tumor cell targeting via NKG2D and the NCRs.
Another clue in favor of an adaptive NK cell profile is the decreased
expression of NKp46 on the surface of CD56negCD16pos NK cells.
In fact, NKp46 is thought to be necessary for immunoregulatory
killing of activated T cells during canonical NK cell function.59 Thus,
increased ADCC, but diminished immunoregulatory NK cell func-
tions, could be influenced by an altered NK cell compartment in eBL
children.
Our study showed that the CD56negCD16pos NK cell subset
expressed proinflammatory cytokines (low IFN-g but high MIP-1b)
after K562 cell stimulation to the same degree as CD56dimCD16pos
NK cells. As previously described,25 IFN-g expression was lower in
CD56neg NK cells, the predominant NK cell subset in eBL
patients, compared with CD56pos NK cells (supplemental
Figure 10). MIP-1b is produced by activated immune cells and has
multiple biological functions, including chemotaxis, degranulation,
Figure 7. Resolution of the CD56neg CD16pos subset from eBL children after chemotherapy. NK cell subsets were defined by CD56 and CD16 expression.
The first time point was before chemotherapy, and the second and third time points were 3 and 9 months, respectively, after diagnosis (during remission). (A) Changes in
the percentage of NK cells were defined as the number of NK cells (CD56pos and/or CD16pos)/total number of live lymphocytes. (B) Changes in the percentage of
CD56negCD16pos NK cells at each time point for 2 eBL patients. (C) Cytograms for the 3 time points for patient “BL1.” Changes in activation (D) and NCR (E) markers over
time for both eBL children (“BL1” and “BL2”) for CD56negCD16pos NK cells. (F) Plots of NKp30/NKp46, NKp30/2B4, and NKp46/2B4 coexpression for CD56negCD16pos NK
cells from an eBL1 patient during the course of treatment, as well as for 3 healthy Nandi children.
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and phagocytosis (reviewed in Maurer and von Stebut48), making it a
key player in inflammation. A study of Ugandan children de-
scribed higher MIP-1b, as well as TNF-a, in serum associated with
malaria.60 However, higher MIP-1b levels were observed in children
who died of severe malaria compared with survivors, in contrast to
TNF-a levels, which were not differentially associated with disease
outcome. High levels of MIP-1b were also described in children from
Gabon with severe malaria, and an in vitro assay confirmed MIP-1b
production by PBMCs after hemozoin stimulation.61 Thus, it is
tempting to speculate that the overexpression of MIP-1b by NK cells
in the absence of TNF-a, within the context of eBL etiology, might
signify an immune adaptation that diminishes EBV immunosurveil-
lance. Mechanistic studies examining the relative killing efficiency of
MIP-1b–secreting NK cells would support this hypothesis.
Understanding the role of NK cells in fighting various cancers will
help to customize NK cell–based immunotherapeutic strategies.
However, within the context of infection-associated cancers, such
as pediatric eBL, an immune equilibrium appears to have been
established to permit asymptomatic chronic malaria and latent EBV
infections in young children as a tradeoff for protection against
pathologic hyperimmune responses.62,63 With their cytotoxic
functions (reviewed in Morvan and Lanier64), NK cells are key
agents to deploy against tumors cells,65 yet knowing the immuno-
logic landscape of patients prior to introducing an immunotherapy
seems essential for the success of such interventions. Results from
our study are the first step in understanding the role of NK cells in
eBL etiology and support the pursuit of 2 NK cell–based therapeutic
approaches that could be considered to improve outcomes for
children diagnosed with eBL: inhibitory KIR3DL1 blockade and
ADCC boosted with tumor neoantigen–targeted antibodies. Our
longitudinal results from an admittedly limited number of eBL survivors
support the scientific rationale that restoring NK cell function could be
of therapeutic benefit.
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